Identification and quantification of the t-FL clonotype in the previous FL samples by RQ-PCR
| Patient, n = 8 . | Sample, n = 10 . | Total no. of primers . | Region* . | Sensitivity primers† . | Amplification level . |
|---|---|---|---|---|---|
| 1 | FL | 4 | CDR1-FR2/CDR2-FR3 | 10-4 | 10-2/10-3 |
| FL | CDR1/FR3 | 10-4 | 10-2/10-3 | ||
| 2 | FL | 3 | FR2-CDR2/FR3 | 10-4 | 10-3 |
| FL | FR2-CDR2/FR3 | 10-4 | 10-3 | ||
| 6 | FL | 4 | FR1-CDR1/FR3 | 10-4 | 10-4 |
| FL | FR1-CDR1/FR3 | 10-4 | 10-4 | ||
| 12 | FL | 4 | FR2-CDR2/FR3-CDR3 | 10-4 | Negative |
| FL | FR2-CDR2/FR3-CDR3 | 10-4 | Negative | ||
| 15 | FL | 3 | CDR1-FR2/FR3 | 10-4 | Negative |
| FL | CDR1-FR2/FR3 | 10-4 | Negative | ||
| 25 | FL | 3 | FR2-CDR2/FR3 | 10-4 | Negative |
| FL | 3 | FR2-CDR2/CDR3 | 10-4 | Negative | |
| FL2‡ | FR2-CDR2/FR3 | 10-4 | Negative | ||
| FL2‡ | FR2-CDR2/FR3 | 10-4 | Negative | ||
| 26 | FL | 3 | FR1-CDR1/FR3 | 10-4 | Negative |
| FL | 3 | FR1-CDR1/FR3 | 10-4 | Negative | |
| FL2‡ | FR1-CDR1/FR3 | 10-4 | 10-1/10-2 | ||
| FL2‡ | FR1-CDR1/FR3 | 10-4 | 10-1/10-2 | ||
| 27 | FL | 4 | FR2-CDR2/CDR3 | 10-4 | 10-1/10-2 |
| FL | FR2-CDR2/CDR3 | 10-4 | 10-1/10-2 |
| Patient, n = 8 . | Sample, n = 10 . | Total no. of primers . | Region* . | Sensitivity primers† . | Amplification level . |
|---|---|---|---|---|---|
| 1 | FL | 4 | CDR1-FR2/CDR2-FR3 | 10-4 | 10-2/10-3 |
| FL | CDR1/FR3 | 10-4 | 10-2/10-3 | ||
| 2 | FL | 3 | FR2-CDR2/FR3 | 10-4 | 10-3 |
| FL | FR2-CDR2/FR3 | 10-4 | 10-3 | ||
| 6 | FL | 4 | FR1-CDR1/FR3 | 10-4 | 10-4 |
| FL | FR1-CDR1/FR3 | 10-4 | 10-4 | ||
| 12 | FL | 4 | FR2-CDR2/FR3-CDR3 | 10-4 | Negative |
| FL | FR2-CDR2/FR3-CDR3 | 10-4 | Negative | ||
| 15 | FL | 3 | CDR1-FR2/FR3 | 10-4 | Negative |
| FL | CDR1-FR2/FR3 | 10-4 | Negative | ||
| 25 | FL | 3 | FR2-CDR2/FR3 | 10-4 | Negative |
| FL | 3 | FR2-CDR2/CDR3 | 10-4 | Negative | |
| FL2‡ | FR2-CDR2/FR3 | 10-4 | Negative | ||
| FL2‡ | FR2-CDR2/FR3 | 10-4 | Negative | ||
| 26 | FL | 3 | FR1-CDR1/FR3 | 10-4 | Negative |
| FL | 3 | FR1-CDR1/FR3 | 10-4 | Negative | |
| FL2‡ | FR1-CDR1/FR3 | 10-4 | 10-1/10-2 | ||
| FL2‡ | FR1-CDR1/FR3 | 10-4 | 10-1/10-2 | ||
| 27 | FL | 4 | FR2-CDR2/CDR3 | 10-4 | 10-1/10-2 |
| FL | FR2-CDR2/CDR3 | 10-4 | 10-1/10-2 |
Each sample is reported twice because the experiments were performed using 2 different combinations of primers and for patient 15 also 2 different probes.
This is the region of the IgH-VH gene where the clonotype primers were designed.
Maximal sensitivity was reported.
In 2 cases (patient 25 and patient 26), 2 sequential FL (FL2) samples were investigated. Patient 25 was negative for the t-FL clone in both the FL samples analyzed, whereas patient 26 was negative in the first FL biopsy and positive, at a level between 10−1 and 10−2, in the second.